Savara Inc. (SVRA) |
| 5.61 0.01 (0.18%) 08-26 16:00 |
| Open: | 5.58 |
| High: | 5.68 |
| Low: | 5.51 |
| Volume: | 1,529,844 |
| Market Cap: | 1,150(M) |
| PE Ratio: | -10.02 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.00 |
| Resistance 1: | 5.99 |
| Pivot price: | 5.56 |
| Support 1: | 5.46 |
| Support 2: | 5.14 |
| 52w High: | 7.005 |
| 52w Low: | 3.194 |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Financials
| EPS | -0.580 |
| Book Value | 0.690 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.423 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -50.2 |
| Return on Equity (ttm) | -105.5 |
Company news
Mon, 24 Aug 2026
Savara (SVRA) to Present Phase 3 IMPALA-2 Trial Data Highlightin - GuruFocus
Sun, 23 Aug 2026
Savara (SVRA) Stock: Ends Up by 1.82% at $5.59 in the Current Update; Level Watch: the $5.31 to $5.87 Range Remains in Focus in the Latest Session - Market Neutral Pair - vinanet.vn
Sun, 23 Aug 2026
Why Savara (SVRA) Is Getting Attention Today - Sahm
Thu, 20 Aug 2026
Savara Announces New Employment Inducement Grant - Business Wire
Sat, 15 Aug 2026
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11 - Triple Top - vinanet.vn
Wed, 12 Aug 2026
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
